Prothena Announces Review On Birtamimab Mechanism Of Action And Pharmacological Characteristics Published In Leukemia & Lymphoma
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced the publication related